[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 1956

Stilbamidine-Resistant North American Blastomycosis: Blastomyces Vaccine Treatment

AMA Arch Derm. 1956;73(6):556-559. doi:10.1001/archderm.1956.01550060026004


Great advances have been made in the treatment of blastomycosis with the advent of stilbamidine and 2-hydroxystilbamidine. The problem of stilbamidine treatment failures is still unanswered. One such case is presented here as it may offer a partial answer to this question.


Schoenbach and associates1 reported in 1951 on the favorable response of systemic blastomycosis to stilbamidine. Arthur Curtis2 reported four cases of blastomycosis cured with stilbamidine and diethylstilbesterol in 1952. One treatment success and one failure were reported at the Chicago Dermatologic Society* likewise in 1952. One of the most comprehensive articles, and one of the best, evaluating stilbamidine and its usage, by Dr. D. T. Smith,5 appeared in GP, 1953. Dr. Smith summarized the background and earlier use of stilbamidine in treatment of blastomycoses, presenting detailed information as to dosage, contraindications, and toxic manifestations, together with a brief presenta